Isoniazid is a cornerstone antibiotic used to treat and prevent tuberculosis (TB). This guide explains what it’s for, who it helps, isoniazid dosage and directions, precautions, contraindications, possible side effects, drug interactions, and what to do about a missed dose or overdose. You’ll also learn about storage and the U.S. prescription policy. Instead of trying to buy isoniazid without a prescription, Surgery Center of Pottsville provides evaluation-led, lawful care coordination—often in collaboration with public health TB programs—to help you access treatment safely and effectively.
Isoniazid is a first-line anti-tuberculosis medicine that targets Mycobacterium tuberculosis by inhibiting synthesis of mycolic acids, a key component of the bacterial cell wall. It is bactericidal against rapidly dividing organisms and bacteriostatic against slower-growing populations, which is why it is used in both prevention and treatment.
Clinically, isoniazid is used in two major settings. First, for latent TB infection (LTBI), isoniazid monotherapy reduces the risk that dormant bacteria will progress to active disease. Classic regimens include daily isoniazid for 6–9 months, often selected for patients who cannot take rifamycin-based options. Second, in active TB disease, isoniazid is part of multi-drug therapy (commonly with rifampin, pyrazinamide, and ethambutol in the initial phase) to prevent resistance and achieve cure. It may also be used as part of therapy for certain non-tuberculous mycobacterial infections based on specialist guidance.
In public health practice, isoniazid is frequently delivered through directly observed therapy (DOT) or similar adherence-support programs to improve outcomes and reduce transmission.
Always follow your clinician’s instructions and local public health protocols. Typical adult doses include: for latent TB infection, 300 mg orally once daily for 6–9 months, or 900 mg twice weekly under DOT. For active TB, 5 mg/kg (up to 300 mg) orally once daily as part of a multi-drug regimen; some regimens use intermittent dosing under DOT. Pediatric dosing is often 10–15 mg/kg once daily (maximum 300 mg), with specialist oversight.
Take isoniazid on an empty stomach—1 hour before or 2 hours after meals—for best absorption. If stomach upset occurs, your clinician may allow taking it with a small snack; avoid aluminum-containing antacids within 1–2 hours of dosing because they can reduce absorption.
Pyridoxine (vitamin B6) is frequently co-prescribed at 25–50 mg daily to reduce the risk of peripheral neuropathy, especially in patients who are pregnant, breastfeeding, older than 50, diabetic, malnourished, living with HIV, have kidney failure, alcohol use disorder, or are on medications that predispose to neuropathy.
Adherence is critical to prevent resistance and treatment failure. If your regimen involves multiple TB drugs, take them exactly as directed, at consistent times, and keep all follow-up visits for laboratory monitoring and clinical assessment.
Hepatotoxicity is the most significant risk associated with isoniazid. The likelihood increases with age, alcohol use, pre-existing liver disease, and concurrent use of other hepatotoxic drugs (e.g., rifampin, acetaminophen in high doses). Tell your healthcare professional about any history of hepatitis, cirrhosis, heavy alcohol use, or abnormal liver tests. Baseline and periodic liver function tests (LFTs) are commonly recommended, especially for higher-risk patients.
Report symptoms of liver injury immediately: fatigue, weakness, poor appetite, nausea, vomiting, right upper abdominal pain, dark urine, light-colored stools, or yellowing of the skin or eyes. Prompt evaluation can prevent severe complications.
Because isoniazid can cause or worsen peripheral neuropathy, discuss risk factors such as diabetes, nutritional deficiencies, renal failure, HIV, alcoholism, and pregnancy. Vitamin B6 supplementation often mitigates this risk.
Isoniazid may interact with numerous medications via CYP450 inhibition and other mechanisms. Provide a full list of prescriptions, over-the-counter products, and supplements. Be cautious with tyramine- or histamine-rich foods (e.g., aged cheeses, cured meats, certain fish), which may cause flushing, palpitations, or headache in some patients due to isoniazid’s weak monoamine oxidase inhibition.
During pregnancy, isoniazid is widely used when indicated; benefits generally outweigh risks. B6 supplementation and careful monitoring are advised. Isoniazid is compatible with breastfeeding; infants should be monitored, and pediatric dosing or prophylaxis should be guided by specialists. Avoid alcohol while taking isoniazid due to additive liver toxicity.
Isoniazid is contraindicated in patients with a known hypersensitivity to the drug and in those with acute liver disease or a history of severe isoniazid-associated hepatitis. Extreme caution—or an alternative regimen—is typically advised for individuals with chronic liver disease, significant alcohol use, or prior severe adverse reactions to isoniazid. In suspected or confirmed active TB, isoniazid must not be used alone; monotherapy can rapidly drive resistance. Combination therapy under expert guidance is the standard of care for active disease.
Common side effects include gastrointestinal upset (nausea, vomiting, abdominal discomfort), fatigue, mild skin rash, and transient elevations in liver enzymes. Many people tolerate isoniazid well, particularly with careful monitoring and B6 supplementation.
Serious reactions require urgent evaluation. Hepatitis is the most important: look for anorexia, persistent nausea, vomiting, abdominal pain, dark urine, or jaundice. Peripheral neuropathy typically presents as tingling, numbness, or burning in the hands or feet; this risk is mitigated with pyridoxine. Less commonly, isoniazid can cause optic neuritis (vision changes, color vision disturbances), seizures, psychosis, mood changes, lupus-like syndrome (joint pain, rash), agranulocytosis or anemia, pancreatitis, and severe cutaneous reactions.
If you experience a new rash, fever without explanation, easy bruising, unusual bleeding, severe fatigue, confusion, or changes in vision or mood, contact your clinician promptly. Do not stop or restart TB medications without medical guidance; abrupt changes can affect resistance and outcomes.
Isoniazid inhibits several cytochrome P450 enzymes, which can increase blood levels of certain drugs. Notable interactions include phenytoin and carbamazepine (risk of toxicity: ataxia, nystagmus, sedation), warfarin (enhanced anticoagulation), theophylline, valproate, benzodiazepines (e.g., diazepam), and certain antidepressants and antipsychotics. Dose adjustments and close monitoring may be required.
Concomitant rifampin, while standard in active TB regimens, can raise the risk of hepatotoxicity; this is one reason for routine liver monitoring and symptom screening. Disulfiram taken with isoniazid has been associated with neuropsychiatric effects; concurrent use warrants caution. High-dose acetaminophen combined with isoniazid may increase liver injury risk; follow dosing limits and discuss analgesic options with your clinician.
Food and OTC interactions matter too. Aluminum-containing antacids reduce isoniazid absorption; separate dosing by at least 1–2 hours. Tyramine- or histamine-rich foods may trigger flushing, headaches, palpitations, or blood pressure changes in some patients. Alcohol increases hepatotoxicity risk and should be avoided during therapy. Always inform your healthcare professional about all medicines and supplements to proactively manage isoniazid interactions.
If you miss a dose, take it as soon as you remember unless it is close to the time for your next dose. If it’s nearly time for the next dose, skip the missed one and resume your regular schedule. Do not double up. For DOT or intermittent regimens, contact your clinic or program for instructions. Consistency is crucial for TB therapy; if adherence becomes difficult, ask about support strategies, reminders, or observed therapy to keep you on track.
Isoniazid overdose is a medical emergency. Early symptoms can include nausea, vomiting, dizziness, slurred speech, and lethargy, rapidly progressing to seizures, metabolic acidosis, and coma. Call emergency services or go to the nearest emergency department immediately. If available and advised by poison control, activated charcoal may be administered shortly after ingestion. In a clinical setting, antidotal therapy with intravenous pyridoxine (vitamin B6) is given in a gram-for-gram amount approximating the isoniazid dose ingested (or a standard dose when unknown), alongside airway protection, seizure control, and correction of metabolic abnormalities.
Because outcomes depend on rapid treatment, do not delay seeking help. Bring the medication bottle and any available information about the ingested amount and timing.
Store isoniazid tablets at room temperature (generally 20–25°C/68–77°F), away from excess heat, moisture, and direct light. Keep in the original, tightly closed container and out of reach of children and pets. Do not use expired medication. If you receive isoniazid as part of a public health program, follow the storage instructions provided with your specific formulation. Dispose of unused or expired medicine according to local guidance—your clinic or pharmacy can advise on safe disposal.
In the United States, isoniazid is a prescription medication. For active TB disease, therapy must be prescribed and closely supervised by a qualified clinician—often in coordination with your local or state public health department. For latent TB infection, treatment decisions follow CDC and public health guidelines. Many jurisdictions provide isoniazid through public health programs at low or no cost, sometimes dispensing directly under medical orders rather than via a retail prescription filled at a pharmacy. This ensures safety monitoring, adherence support (e.g., DOT or video DOT), and prompt management of side effects.
Attempting to buy isoniazid without prescription is not recommended and may be unlawful. It also bypasses essential evaluation for active disease, drug resistance, drug interactions, and liver risk. Proper diagnosis—often including a TB skin test or interferon-gamma release assay, chest imaging, and clinical assessment—is critical before starting therapy.
Surgery Center of Pottsville offers a legal, structured pathway to access TB care. Our clinicians provide evaluation, confirm indications for treatment, order necessary labs and imaging, and, when appropriate, issue prescriptions or coordinate directly with public health TB programs that dispense medication under medical orders. This model gives you compliant access without unsafe workarounds, supports adherence, and ensures you receive pyridoxine supplementation and liver monitoring as indicated. To get started, contact our team to schedule an appointment; we will guide you through evidence-based next steps and connect you to resources that fit your clinical needs and local policy.
Isoniazid is a first-line antibiotic for tuberculosis (TB). It is used with other drugs to treat active TB and can be used alone or with a rifamycin to prevent TB in people with latent TB infection (LTBI).
Isoniazid is a prodrug activated by a bacterial enzyme (KatG). Once activated, it blocks the synthesis of mycolic acids—key building blocks of the Mycobacterium tuberculosis cell wall—leading to bacterial death.
No. Using isoniazid alone for active TB quickly leads to resistance. Active TB must be treated with a multidrug regimen, commonly isoniazid, rifampin, pyrazinamide, and ethambutol (RIPE) initially.
Isoniazid is usually taken once daily on an empty stomach for best absorption (1 hour before or 2 hours after meals). If stomach upset occurs, it can be taken with a small snack. Typical adult dose is 300 mg daily (or 5 mg/kg), adjusted by your clinician.
Common effects include nausea, stomach upset, mild elevation of liver enzymes, fatigue, and tingling in hands or feet (peripheral neuropathy). Many people tolerate the medicine well with monitoring.
Stop the medication and seek care urgently if you develop symptoms of hepatitis (loss of appetite, nausea, vomiting, dark urine, pale stools, abdominal pain, jaundice), severe fatigue, confusion, persistent numbness/weakness, rash with fever, or severe mood changes. Your clinician may stop isoniazid if liver enzymes are more than 5 times the upper limit of normal without symptoms, or more than 3 times with symptoms.
Take pyridoxine (vitamin B6) as advised. Most adults at risk are given 25–50 mg daily. Supplementation is especially important if you are pregnant, breastfeeding, malnourished, living with HIV, have diabetes, kidney failure, alcohol use disorder, or are a “slow acetylator.”
Everyone should be assessed monthly for side effects. Baseline liver tests are recommended for patients with risk factors (age >35, pregnancy or postpartum, chronic liver disease, alcohol use, HIV, other hepatotoxic drugs). Ongoing labs are guided by symptoms and risk.
Avoid or strictly limit alcohol. Alcohol significantly increases the risk of liver inflammation and hepatitis while on isoniazid.
Isoniazid is generally considered safe in pregnancy and during breastfeeding when benefits outweigh risks. Vitamin B6 is recommended for the mother, and infants receiving isoniazid should also get pyridoxine. Liver enzymes are often monitored more closely during pregnancy and the immediate postpartum period.
Isoniazid inhibits certain liver enzymes and can increase levels of drugs like phenytoin, carbamazepine, valproate, some benzodiazepines, and warfarin. Aluminum-containing antacids reduce isoniazid absorption (separate by at least 2 hours). Always provide your clinician with a full medication list.
Tyramine- and histamine-rich foods (aged cheeses, cured meats, certain fish like tuna, some wines or fermented products) may cause flushing, headache, or palpitations in some people. If you notice these reactions, limit those foods. Avoid alcohol.
Take the missed dose as soon as you remember the same day. If it is almost time for your next dose, skip the missed one—do not double up. Consistency matters for preventing resistance; consider reminders or pillboxes.
For latent TB, common options include 6 months (6H) or 9 months (9H) of daily isoniazid, or shorter combinations with rifamycins (e.g., 3 months of weekly isoniazid plus rifapentine [3HP]). For active TB, isoniazid is part of a 6-month multidrug regimen in most drug-susceptible cases.
Yes. People who are “slow acetylators” (NAT2 variants) may have higher drug levels, increasing the risk of neuropathy and other side effects, while “rapid acetylators” may have lower levels. Testing isn’t routine, but clinicians consider risk factors and monitor closely.
Yes. Isoniazid is used safely and effectively in children for LTBI and active TB as part of combination therapy. Dosing is weight-based, and vitamin B6 is used in at-risk children or those with symptoms of neuropathy.
Overdose can cause severe nausea, vomiting, seizures, metabolic acidosis, and coma. It is a medical emergency. Treatment includes high-dose intravenous pyridoxine and supportive care in a hospital.
Store at room temperature, away from moisture and light, and keep out of reach of children. Do not use past the expiration date. Dispose of unused tablets according to local guidance or pharmacy take-back programs.
Mild, transient elevations in liver enzymes are relatively common and often resolve without stopping therapy. Your clinician will decide whether to continue, repeat labs, or hold treatment based on values and symptoms.
Both are effective. Rifampin for 4 months (4R) is shorter, has fewer hepatotoxic events, and often better completion. Isoniazid for 6–9 months (6H/9H) is longer and has more hepatotoxicity but fewer drug–drug interactions than rifampin.
The 3HP regimen (isoniazid plus rifapentine once weekly for 12 doses) is shorter and typically has higher completion rates than 6–9 months of isoniazid alone, with comparable protection against TB reactivation when taken as directed.
Rifampin has many more interactions as a potent enzyme inducer, lowering levels of many drugs (e.g., contraceptives, anticoagulants, antiretrovirals). Isoniazid inhibits some enzymes and can raise levels of certain anticonvulsants and warfarin, but its interaction profile is generally narrower.
Isoniazid blocks mycolic acid synthesis; pyrazinamide disrupts mycobacterial energy and membrane function. Pyrazinamide is used only in the intensive phase of active TB and can cause hyperuricemia and arthralgia. Isoniazid is used throughout treatment and for LTBI; its hallmark risks are hepatotoxicity and neuropathy.
Isoniazid commonly causes neuropathy and hepatitis. Ethambutol’s signature risk is optic neuritis (color vision changes and decreased visual acuity). Ethambutol is bacteriostatic and used to prevent resistance early; isoniazid is bactericidal and central to most regimens.
Fluoroquinolones are typically reserved for drug-resistant TB or intolerance to first-line drugs. They are potent but can cause QT prolongation, tendinopathy, and CNS effects. Isoniazid remains first-line for drug-susceptible TB and LTBI.
For drug-susceptible TB, isoniazid is preferred due to efficacy and tolerability profile. Linezolid is used in multidrug-resistant TB and can cause bone marrow suppression, peripheral and optic neuropathy, and lactic acidosis with longer use.
Aminoglycosides are injectable agents used mainly for resistant TB. They can cause hearing loss and kidney injury. Isoniazid is oral, core to first-line therapy, and does not cause ototoxicity or nephrotoxicity, but carries hepatic and neuropathy risks.
Bedaquiline targets mycobacterial ATP synthase and is used in MDR-TB. It can prolong the QT interval and cause hepatotoxicity. Isoniazid targets cell-wall synthesis and is used broadly in drug-susceptible TB and LTBI. They are not interchangeable and are used in different clinical contexts.
Short-course regimens like 4 months of rifampin (4R) or 3 months of weekly isoniazid plus rifapentine (3HP) often achieve higher completion with similar or better safety compared to 6–9 months of isoniazid alone, especially when drug interactions are manageable.
Three months of daily isoniazid plus rifampin (3HR) is shorter and has higher completion rates than 6–9 months of isoniazid alone, with similar protection against TB reactivation, but carries rifampin-related interaction considerations.
Ethionamide and prothionamide share a similar target (mycolic acid synthesis) but are second-line due to frequent GI intolerance, weight loss, hypothyroidism, and more toxicity. Isoniazid is preferred when the strain is susceptible, given better efficacy and tolerability.
All first-line drugs play complementary roles. Isoniazid and rifampin are the backbone for sterilizing and preventing relapse, pyrazinamide shortens therapy by killing semi-dormant bacilli, and ethambutol protects against resistance while susceptibilities are confirmed.